ZYXI on NASDAQ

Zynex

Logo: zynexmed.com4

Medical device manufacturer

Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

2001Founded1

Compare with Axogen, Inc., Outset Medical, Inc. or ViewRay, or pick any stock.

  • TickerZYXI on NASDAQ1
  • Industrymedical technology1
  • HeadquartersEnglewood1
  • Websitewww.zynexmed.com
  • Incorporated inNV5
  • Business address9655 Maroon Circle, Englewood, Co 801125
  • Filer categoryAccelerated filer, Smaller reporting company5
Zynex Medical Tranparent Background
Photo: Dzwygart, CC BY-SA 4.0, via Wikimedia Commons7

Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring. Thomas Sandgaard founded Zynex Medical in 1996.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

3.1%Operating margin8
1.6%Net margin8
4.4%Revenue growth, 20248
8.4%Return on equity8
$12.1MFree cash flow8

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue20¢$39.4M
  • Research and development6¢$12.0M
  • Other costs71¢$137.3M
  • Income tax0¢$633.0K
  • Profit2¢$3.0M

Out of $192.4M in revenue.8

Where each dollar of operating cash went, fiscal 2024

  • Capital spending4¢$578.0K
  • Dividends paid0¢$9.0K
  • Share buybacks96¢$15.6M

Out of $12.7M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.8

Financial statements

Revenue9101112138$192.4M in 2024+503% since 2018
0$50.0M$100.0M$150.0M$200.0M2018: $31.9M$31.9M20182019: $45.5M$45.5M2019+42%2020: $80.1M$80.1M2020+76%2021: $130.3M$130.3M2021+63%2022: $158.2M$158.2M2022+21%2023: $184.3M$184.3M2023+17%2024: $192.4M$192.4M2024+4%
Operating income9101112138$6.0M in 2024−42% since 2018
0$10.0M$20.0M$30.0M2018: $10.4M$10.4M20182019: $11.1M$11.1M2019+7%2020: $10.2M$10.2M2020−7%2021: $22.4M$22.4M2021+118%2022: $22.9M$22.9M2022+3%2023: $10.8M$10.8M2023−53%2024: $6.0M$6.0M2024−44%
Net income9101112138$3.0M in 2024−69% since 2018
0$5.0M$10.0M$15.0M$20.0M2018: $9.6M$9.6M20182019: $9.5M$9.5M2019−1%2020: $9.1M$9.1M2020−4%2021: $17.1M$17.1M2021+88%2022: $17.0M$17.0M2022−0%2023: $9.7M$9.7M2023−43%2024: $3.0M$3.0M2024−69%
Fiscal year2018201920202021202220232024
Revenue$31.9M9$45.5M10$80.1M11$130.3M12$158.2M13$184.3M8$192.4M8
Cost of revenue$6.0M9$8.8M10$17.4M11$27.3M12$32.0M13$38.4M8$39.4M8
Research and development$200.0K9$600.0K10$800.0K11$2.6M12$7.1M13$9.2M8$12.0M8
Selling, general and admin$15.5M16
Operating expenses$107.9M12$135.2M13$173.5M8$186.4M8
Operating income$10.4M9$11.1M10$10.2M11$22.4M12$22.9M13$10.8M8$6.0M8
Interest$154.0K16
Income before tax$22.3M12$22.2M13$12.6M8$3.6M8
Income tax$664.0K9$2.4M10$1.1M11$5.2M12$5.2M13$2.8M8$633.0K8
Net income$9.6M9$9.5M10$9.1M11$17.1M12$17.0M13$9.7M8$3.0M8
Earnings per share$0.299$0.2910$0.2411$0.4512$0.4413$0.278$0.098
Earnings per share (diluted)$0.289$0.2810$0.2411$0.4412$0.4413$0.278$0.098
Shares (weighted, basic)38.3M shares1238.5M shares1335.6M shares831.9M shares8
Shares (weighted, diluted)39.2M shares1239.1M shares1336.1M shares832.3M shares8

Compare Zynex with another company

The story

In 1996, Thomas Sandgaard founded Zynex Medical as a wholesaler of electrotherapy products. Sandgaard began working with medical devices in his native Denmark and immigrated to the United States with plans to open a medical devices business. He launched his company in a one-bedroom apartment with $4,000 and a credit card. In 1998, the company received its first Food and Drug Administration approval for one of its products, “an electric-stimulation device that managed pain and increased blood circulation to promote healing.”

The company went public in 2004. In 2008, the company changed its name from Zynex Medical Holdings to Zynex and began trading on the OTC Bulletin Board under the symbol ZYXI. It relocated from Lone Tree, Colorado to Englewood, Colorado in early 2018.

In February 2010, Zynex restructured its business into three subsidiaries: Zynex Medical, Zynex Monitoring Solutions and Zynex NeuroDiagnostic. Zynex Medical manufactures electrotherapy devices for pain management and physical rehabilitation; Zynex Monitoring Solutions manufactures devices for non-invasive cardiac monitoring; and Zynex NeuroDiagnostic manufactures devices for neurological diagnosis.

In March 2012, Zynex Medical acquired the assets of NeuroDyne Medical. NeuroDyne Medical was a Cambridge, Massachusetts-based manufacturer of “medical devices for non-invasive measurement of surface electromyography and autonomic nervous systems.” NeuroDyne Medical was folded into Zynex's NeuroDiagnostic subsidiary.

In February 2019, Zynex Medical began trading on Nasdaq under the symbol ZYXI.

In February 2020, Zynex received FDA clearance for their CM-1500 Cardiac Monitor.

In December 2025, Zynex filed for Chapter 11 bankruptcy protection in an effort to receive new financing from its lenders and resolve pending federal investigations into its billing practices. Zynex admitted to participating in a conspiracy to commit health care fraud, securities fraud, mail fraud, and other violations in a February 2026 court filing to enter into a non-prosecution agreement.

From Wikipedia’s article on Zynex, shared under CC BY-SA 4.0.6

Leadership

Who has led Zynex, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (10)

Products and brands

  • medical device

Listed on Wikidata.1

Former names

  • ZYNEX MEDICAL HOLDINGS INCOct 7, 2005 to Jul 8, 20085
  • ZYNEX MEDICAL HOLDINGS INCFeb 4, 2004 to Aug 12, 20055
  • FOX RIVER HOLDINGS INCNov 26, 2003 to Jan 20, 20045
  • ARIZONA VENTURES INCFeb 14, 2003 to Aug 19, 20035
  • CHINA GLOBAL DEVELOPMENT INCJan 31, 2002 to Jan 15, 20035
  • IBONZAI COM INCNov 14, 2000 to Jun 12, 20015
  • LIFE MEDICAL TECHNOLOGIES INC /UT/Jul 30, 1999 to May 25, 20005

Timeline

  1. Sep 2, 2025New chief executive Steven Lewis Dyson becomes CEO17
  2. Jul 9, 2018New chief executive Thomas Sandgaard becomes CEO18
  3. 2001Founded Founded1

Filings

283 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 67 major events, 163 insider forms, 4 large holders, 30 other. The latest 20:

  1. Mar 27, 20264 EDGAR
  2. Mar 27, 20264 EDGAR
  3. Mar 27, 20264 EDGAR
  4. Mar 26, 202615-12G EDGAR
  5. Mar 26, 20268-K EDGAR
  6. Mar 26, 2026S-8 POS EDGAR
  7. Mar 26, 2026S-8 POS EDGAR
  8. Mar 20, 20268-K EDGAR
  9. Mar 18, 2026EFFECT EDGAR
  10. Mar 13, 2026RW EDGAR
  11. Mar 13, 2026POS AM EDGAR
  12. Feb 19, 20268-K EDGAR
  13. Feb 18, 20268-K EDGAR
  14. Feb 11, 20268-K EDGAR
  15. Feb 2, 20268-K EDGAR
  16. Jan 23, 202625-NSE/A EDGAR
  17. Jan 23, 202625-NSE EDGAR
  18. Jan 23, 20268-K EDGAR
  19. Jan 15, 20268-K EDGAR
  20. Dec 18, 20258-K EDGAR

The 283 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

25 open-market trades by officers, directors and large owners since October 2021: 1 buys and 24 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 3, 2025MOORHEAD DANIEL JCHIEF FINANCIAL OFFICERSale10,000$7.15$71.5KForm 4
Feb 3, 2025MOORHEAD DANIEL JCHIEF FINANCIAL OFFICERSale10,000$7.68$76.8KForm 4
Jan 2, 2025MOORHEAD DANIEL JCHIEF FINANCIAL OFFICERSale10,000$7.88$78.8KForm 4
Dec 2, 2024MOORHEAD DANIEL JCHIEF FINANCIAL OFFICERSale10,000$8.08$80.8KForm 4
Nov 14, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$8.09$16.2KForm 4
Nov 13, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$8.37$16.7KForm 4
Nov 12, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$9.24$18.5KForm 4
Nov 11, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$9.09$18.2KForm 4
Nov 8, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$8.77$17.5KForm 4
Nov 7, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$9.17$18.3KForm 4
Nov 6, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$8.82$17.6KForm 4
Nov 5, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$8.05$16.1KForm 4
Nov 4, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$8.67$17.3KForm 4
Nov 1, 2024MOORHEAD DANIEL JCHIEF FINANCIAL OFFICERSale10,000$8.59$85.9KForm 4
Nov 1, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$8.63$17.3KForm 4
Oct 31, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$8.82$17.6KForm 4
Oct 30, 2024Sandgaard ThomasPresident, CEO and ChairmanSale2,000$8.92$17.8KForm 4
Aug 7, 2024Lucsok AnnaCHIEF OPERATING OFFICERSale8,083$8.03$64.9KForm 4
Aug 6, 2024Lucsok AnnaCHIEF OPERATING OFFICERSale16,792$8.01$134.5KForm 4
Jul 30, 2024MOORHEAD DANIEL JCHIEF FINANCIAL OFFICERSale15,000$8.24$123.6KForm 4

All 25 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.